Eli Lilly's Foundayo obesity pill received 1,390 prescriptions in its first two days of launch around April 9, according to IQVIA data shared with analysts1.
By comparison, Novo Nordisk's Wegovy pill had 3,071 prescriptions over its full first week starting January 51.
Analysts at RBC Capital Markets view Foundayo's early performance as 'encouraging' and indicative of a robust launch, potentially achieving half of Wegovy's first-month trajectory1.
Lilly shares rose about 2% in early trading following the prescription data1.
FDA has requested post-marketing safety data from Lilly on Foundayo (orforglipron), including risks like liver injury and cardiovascular events2.
Sources:
1. https://www.biopharmadive.com/news/foundayo-launch-openai-rosalind-janux-gilead-arcellx/817789/